ArticleAAPS PharmSciTech2026
Carvedilol Pharmaceutical Cocrystals: Preparation, Advanced Characterization and Dissolution Behavior.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The work aims to improve the solubility and dissolution rate of the cardiovascular drug carvedilol (CVD) of II class BCS by a co-crystallization approach. The slurry method was used to preparation of CVD cocrystals. The existence of new solid phases was confirmed by PXRD, DSC, TGA, FTIR and UV-vis spectroscopy. The dissolution kinetics of two component systems in a model buffer solution was studied by the classical shake flask method. The process of CVD release from co-crystals tablets were studied in accordance with Pharmacopoeia standard using a dissolution tester. Pharmaceutical cocrystals of CVD with two coformers, 2-hydroxybenzamide (2OHBZA) and 4-hydroxybenzamide (4OHBZA) in molar ratio 1:1, have been obtained for the first time. Thermodynamic characteristics of the cocrystallization reaction of the active pharmaceutical ingredient with the selected coformers have been experimentally determined for the synthesized CVD/2OHBZA and CVD/4OHBZA cocrystals. It has been shown that the process of cocrystal formation is enthalpy-determined, which is typical for most two-component crystals. Kinetic solubility profiles of new solid phases have been determined in a buffer solution pH 7.4, simulating the pH of blood plasma. It was found that the equilibrium solubility of co-crystal forms of carvedilol significantly exceeds the solubility of original drug. In vitro study of the release of CVD from co-crystal tablets showed a improving of the drug release rate into solution to 67% for CVD/2OHBZA and 43% for CVD/4OHBZA, that by 2.6 and 1.7 times higher then the raw drug. Considering the significant enhancement of carvedilol solubility in two-component systems and their stability in aqueous medium, co-crystallization is a promising approach for the development of new dosage forms of this drug with improved bioavailability.
Indexed as
Identifiers
41565914What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.